Ironwood Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 267
- Market Cap
- $782.7M
- Introduction
Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.
Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
- Conditions
- Interventions
- First Posted Date
- 2007-04-16
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 420
- Registration Number
- NCT00460811
- Locations
- 🇨🇦
Microbia Investigational Site, Saskatoon, Saskatchewan, Canada
Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia
- Conditions
- First Posted Date
- 2006-11-27
- Last Posted Date
- 2007-10-01
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT00404001
- Locations
- 🇺🇸
Microbia Investigational Site, Olympia, Washington, United States
Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation
- Conditions
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2013-03-05
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 310
- Registration Number
- NCT00402337
- Locations
- 🇺🇸
Microbia Investigational Site, Madison, Wisconsin, United States
Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation
- Conditions
- First Posted Date
- 2006-03-24
- Last Posted Date
- 2009-03-24
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00306748
- Locations
- 🇺🇸
Arkansas Gastroenterology, North Little Rock, Arkansas, United States
🇺🇸Memphis Gastroenterology Clinic, Germantown, Tennessee, United States
🇺🇸Consultants for Clinical Research of South Florida, Boynton Beach, Florida, United States
Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS
- Conditions
- First Posted Date
- 2005-11-24
- Last Posted Date
- 2006-10-20
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT00258193
- Locations
- 🇺🇸
Mayo Clinic Foundation, Rochester, Minnesota, United States